Since its establishment in 1975 as Taerim Industry, the company name was changed to Taerim Pharmaceutical in 1988. Since then, we became one of the leading R&D-oriented biotechnology venture through its continuous efforts to develop unique medicines for the improvement of human health and eradication of diseases. We are the industry leader in the field of hepatitis medicine.

After the introduction of the Substance Patent System in 1987, we realized that the future of medicine manufacturers would depend on developing competitive medicines. We have been investing more than 20% of its total sales into R&D for the development of new medicines. As a result, the first hepatitis medicine in Korea named "Nissel" was developed in July 1990.

Furthermore, after obtaining a patent for a new hepatitis medicine and completing the phase III clinical trial, "Pennel" was launched in Feb. 1998. At the present, "Pennel" capsule is the most popular drug against the hepatitis in Korea and its superiority has been widely recognized in numerous Southeast Asian countries including Vietnam. Recently, Taerim started to export "Pennel" to Egypt.

Through extensive experience in research and development, we strive to constantly develop new drugs for the treatment against adult diseases using natural substances. For the first time in the world, we obtained the patent on the hepatitis C drug and is actively preparing to commercialize it.

Since our establishment, we have made every effort to improve the health of people around the world. We will continue to exert our best to become a respectful company that thrives to make the world without any diseases.

Thank you for your interest and encouragement.